PropertyValue
?:abstract
  • COVID-19 utilizes the ACE2 pathway as a means of infection Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death The source of this heterogeneity is likely multifaceted and may have a genetic component Demographic and clinical comorbidities associated with the severity of infection suggest that possible variants known to influence the renin-angiotensin-aldosterone (RAAS) system pathway (particularly those that influence ACE2) may contribute to the heterogenous infection response ACE2 and Ang(1-7) (the product of ACE2) seem to have a protective effect on the pulmonary and cardiac systems Hypertension medication modulation, may alter ACE2 and Ang(1-7), particularly in variants that have been shown to influence RAAS system function, which could be clinically useful in patients with COVID-19
?:creator
?:journal
  • Pharmacogenomics
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations
?:type
?:who_covidence_id
  • #655135
?:year
  • 2020

Metadata

Anon_0  
expand all